Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Translate Bio, Inc.    TBIO

TRANSLATE BIO, INC.

(TBIO)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Translate Bio : Shares Gain After FDA Grants Rare Pediatric Disease Designation

share with twitter share with LinkedIn share with facebook
share via e-mail
03/27/2020 | 06:50am EDT

By Chris Wack

 

Translate Bio Inc. shares were up 12% to $11.50 after the company said the U.S. Food and Drug Administration has granted rare pediatric disease designation for MRT5005 for the treatment of cystic fibrosis.

MRT5005 is designed to deliver mRNA encoding fully functional cystic fibrosis transmembrane conductance regulator protein to cells in the lung through nebulization.

The therapeutics company said it anticipates Covid-19-related interruptions in enrollment, dosing and follow-up in the ongoing phase 1/2 clinical trial in patients with cystic fibrosis. The company will provide updated timing on the expected interim data readout of the additional single-ascending dose group and the multiple-ascending dose portion of the clinical trial at a later date.

TranslateBio also said it was working with French pharmaceutical company Sanofi SA to develop a new mRNA vaccine candidate against Covid-19, the disease caused by the new coronavirus.

 

Write to Chris Wack at chris.wack@wsj.com

 

Stocks mentioned in the article
ChangeLast1st jan.
SANOFI SA -0.06% 88.76 Real-time Quote.-0.89%
TRANSLATE BIO, INC. -1.79% 19.47 Delayed Quote.143.73%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on TRANSLATE BIO, INC.
05/28Translate Bio to Present at Jefferies Virtual Healthcare Conference
GL
05/12Translate Bio to Present at the Bank of America Securities Virtual 2020 Healt..
GL
05/07Translate Bio Announces First Quarter 2020 Financial Results and Provides Co..
GL
05/07TRANSLATE BIO : Management's Discussion and Analysis of Financial Condition and ..
AQ
05/05EXCLUSIVE : Sanofi to enroll thousands for its coronavirus vaccine trials
RE
04/25SPECIAL REPORT : Countries, companies risk billions in race for coronavirus vacc..
RE
04/24TRANSLATE BIO : Shares Rise After Hours Following 23.6% Gain in Regular Session
DJ
04/07TRANSLATE BIO, INC. : Other Events (form 8-K)
AQ
03/30SANOFI : Pasteur and Translate Bio to Collaborate to Develop a Novel mRNA Vaccin..
AQ
03/27TRANSLATE BIO : Shares Gain After FDA Grants Rare Pediatric Disease Designation
DJ
More news
Financials (USD)
Sales 2020 10,9 M - -
Net income 2020 - - -
Net Debt 2020 - - -
P/E ratio 2020 -
Yield 2020 -
Capitalization 1 249 M 1 249 M -
EV / Sales 2019
Capi. / Sales 2020 114x
Nbr of Employees 93
Free-Float 82,1%
Chart TRANSLATE BIO, INC.
Duration : Period :
Translate Bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TRANSLATE BIO, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 20,33 $
Last Close Price 19,85 $
Spread / Highest target 25,9%
Spread / Average Target 2,43%
Spread / Lowest Target -14,4%
Managers
NameTitle
Ronald C. Renaud President, Chief Executive Officer & Director
Daniel S. Lynch Chairman
Paul Burgess Secretary, Chief Operating & Legal Officer
John R. Schroer CFO, Treasurer & Principal Accounting Officer
Ann Barbier Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
TRANSLATE BIO, INC.143.73%1 249
GILEAD SCIENCES12.74%91 895
VERTEX PHARMACEUTICALS29.83%73 705
REGENERON PHARMACEUTICALS64.50%70 764
WUXI APPTEC CO., LTD.18.54%25 389
GENMAB A/S33.95%19 425